Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Differences of Behavioral and Psychological Symptoms of Dementia in Disease Severity in Four Major Dementias.

Kazui H, Yoshiyama K, Kanemoto H, Suzuki Y, Sato S, Hashimoto M, Ikeda M, Tanaka H, Hatada Y, Matsushita M, Nishio Y, Mori E, Tanimukai S, Komori K, Yoshida T, Shimizu H, Matsumoto T, Mori T, Kashibayashi T, Yokoyama K, Shimomura T, Kabeshita Y, Adachi H, Tanaka T.

PLoS One. 2016 Aug 18;11(8):e0161092. doi: 10.1371/journal.pone.0161092. eCollection 2016.

2.

Improving the management of behaviour that challenges associated with dementia in care homes: protocol for pharmacy-health psychology intervention feasibility study.

Maidment ID, Shaw RL, Killick K, Damery S, Hilton A, Wilcock J, Barnes N, Brown G, Gillespie S, Fox C, Barton G, Iliffe S, Seare N.

BMJ Open. 2016 Mar 23;6(3):e010279. doi: 10.1136/bmjopen-2015-010279.

3.

Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.

Szeto JY, Lewis SJ.

Curr Neuropharmacol. 2016;14(4):326-38. Review.

4.

Dietary and donepezil modulation of mTOR signaling and neuroinflammation in the brain.

Dasuri K, Zhang L, Kim SO, Bruce-Keller AJ, Keller JN.

Biochim Biophys Acta. 2016 Feb;1862(2):274-83. doi: 10.1016/j.bbadis.2015.11.002. Epub 2015 Nov 10.

5.

Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled Trial.

Zhang Y, Lin C, Zhang L, Cui Y, Gu Y, Guo J, Wu D, Li Q, Song W.

PLoS One. 2015 Jun 15;10(6):e0130353. doi: 10.1371/journal.pone.0130353. eCollection 2015.

6.

Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors.

Leinonen A, Koponen M, Hartikainen S.

PLoS One. 2015 May 1;10(5):e0124500. doi: 10.1371/journal.pone.0124500. eCollection 2015. Review.

7.

Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer's patients in long-term care health facilities.

Meguro K, Ouchi Y, Akanuma K, Meguro M, Kasai M.

BMC Neurol. 2014 Dec 17;14:243. doi: 10.1186/s12883-014-0243-7.

8.

Depressive Symptoms in Clinical and Incipient Alzheimer's Disease.

Hsiao JJ, Teng E.

Neurodegener Dis Manag. 2013;3(2):147-155.

9.

Effect of medications on physical function and cognition in nursing home residents with dementia.

Dutcher SK, Rattinger GB, Langenberg P, Chhabra PT, Liu X, Rosenberg PB, Leoutsakos JM, Simoni-Wastila L, Walker LD, Franey CS, Zuckerman IH.

J Am Geriatr Soc. 2014 Jun;62(6):1046-55. doi: 10.1111/jgs.12838. Epub 2014 May 13.

10.

Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

Herrmann N, Lanctôt KL, Hogan DB.

Alzheimers Res Ther. 2013 Jul 8;5(Suppl 1):S5. doi: 10.1186/alzrt201. Epub 2013 Jul 8.

11.

Predictors of decline in walking ability in community-dwelling Alzheimer's disease patients: Results from the 4-years prospective REAL.FR study.

Rolland Y, Cantet C, Barreto Pde S, Cesari M, Abellan van Kan G, Vellas B.

Alzheimers Res Ther. 2013 Oct 29;5(5):52. doi: 10.1186/alzrt216. eCollection 2013.

12.

Use of the Tailored Activities Program to reduce neuropsychiatric behaviors in dementia: an Australian protocol for a randomized trial to evaluate its effectiveness.

O'Connor CM, Clemson L, Brodaty H, Jeon YH, Mioshi E, Gitlin LN.

Int Psychogeriatr. 2014 May;26(5):857-69. doi: 10.1017/S1041610214000040. Epub 2014 Feb 10.

13.

Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.

Parsons CG, Danysz W, Dekundy A, Pulte I.

Neurotox Res. 2013 Oct;24(3):358-69. doi: 10.1007/s12640-013-9398-z. Epub 2013 May 9. Review.

14.

Pharmacotherapeutic management of dementia across settings of care.

Rattinger GB, Burcu M, Dutcher SK, Chhabra PT, Rosenberg PB, Simoni-Wastila L, Franey CS, Walker LD, Zuckerman IH.

J Am Geriatr Soc. 2013 May;61(5):723-33. doi: 10.1111/jgs.12210. Epub 2013 Apr 16.

15.
16.

Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET).

Drye LT, Scherer RW, Lanctôt KL, Rosenberg PB, Herrmann N, Bachman D, Mintzer JE; ADMET Research Group.

Am J Geriatr Psychiatry. 2013 Jun;21(6):549-59. doi: 10.1016/j.jagp.2012.12.018. Epub 2013 Jan 18.

17.

Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy.

Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D.

Alzheimers Res Ther. 2013 Jan 21;5(1):6. doi: 10.1186/alzrt160. eCollection 2013.

18.

Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial.

Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators.

Ann Neurol. 2012 Jul;72(1):41-52. doi: 10.1002/ana.23557.

19.

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.

Tariot P, Salloway S, Yardley J, Mackell J, Moline M.

BMC Res Notes. 2012 Jun 8;5:283. doi: 10.1186/1756-0500-5-283.

20.

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.

Hartz S, Getsios D, Tao S, Blume S, Maclaine G.

BMC Neurol. 2012 Feb 8;12:2. doi: 10.1186/1471-2377-12-2.

Supplemental Content

Support Center